Clinical Trial

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated April 14, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-15
notable Enrollment reduced: 140 -> 121 participants 2026-04-15
notable Primary completion pushed: 2026-03-31 -> 2026-06-30 2026-04-15
minor Completion moved earlier: 2026-09-30 -> 2026-06-30 2026-04-15
Trial Details
NCT Number NCT05023486
Lead Sponsor Novita Pharmaceuticals, Inc.
Conditions Advanced or Metastatic Solid Tumor Malignancies
Enrollment 121 participants
Start Date 2021-12-07
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-14